Wire · opportunities
Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Quantum BioPharma has received FDA clearance to proceed with a Phase 2 trial of Lucid-MS, a first-in-class neuroprotective therapy targeting demyelination in progressive multiple sclerosis, addressing a significant unmet medical need. The Phase 2 trial is randomized, double-blind, and placebo-controlled, aiming to evaluate efficacy, safety, and tolerability in patients with progressive MS forms.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now engage with a new mandated clinical trial path that opens the US progressive MS market for neuroprotective drugs, changing how you prioritise your pipeline investment and partnerships. Your next move should be to map clinical and patient recruitment opportunities fast, as this trial will define the competitive landscape.
◆ Coverage
1 source · 10 Aug 2026
◆ Related on Wire
◆ Topics